Ligand Pharmaceuticals Details XOMA Royalty Acquisition Impact, Raises 2026 Guidance
LGND has more than doubled off its 52-week low of $98.89.
Summary
Ligand Pharmaceuticals provided detailed financial projections and updated 2026 guidance following its $739 million acquisition of XOMA Royalty Corporation, highlighting significant accretion to earnings and portfolio expansion.
Key Events · M&A and Partnerships · LGND
-
Acquisition Details Confirmed
Ligand Pharmaceuticals provided an investor presentation transcript detailing the $739 million acquisition of XOMA Royalty Corporation, expected to close in Q3 2026.
-
Raised 2026 Financial Guidance
The company increased its full-year royalty revenue guidance to $225M-$250M (from $200M-$225M) and total revenue guidance to $270M-$310M (from $245M-$285M).
-
Significant EPS Accretion Projected
Adjusted core EPS guidance for 2026 was raised to $8.50-$9.50 (from $8-$9), with the acquisition expected to add $0.50 to 2026 EPS and $1.50 to 2027 EPS.
-
Portfolio Expansion and Growth Acceleration
The acquisition will add seven commercial royalties, including key programs like Vabysmo, Ojemda, and Miplyffa, and over 100 partnered development-stage programs, more than doubling Ligand's portfolio size.
Analysis · LGND · Life Sciences
This filing provides the detailed financial and strategic rationale behind Ligand Pharmaceuticals' recently announced $739 million acquisition of XOMA Royalty Corporation. It quantifies the expected positive impact on Ligand's financials, including a significant increase in 2026 and 2027 adjusted EPS, and raises the company's full-year royalty and total revenue guidance. The acquisition is strategically important as it substantially expands Ligand's royalty portfolio with seven new commercial assets and over 100 development-stage programs, accelerating long-term growth without shareholder dilution. The company noted that despite trading near 52-week highs, they believe their stock is undervalued, justifying the all-cash, non-dilutive funding approach.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGND was trading at $241.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $98.89 to $247.38. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.